Affibody AB and Daiichi Sankyo enter into a License Agreement regarding the Albumod™ platform

Non-Regulatory

June 25, 2013

Solna, Sweden, June 25, 2013. Affibody is pleased to announce a collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568).

Affibody AB and Daiichi Sankyo have signed a License Agreement regarding the use of Affibody’s proprietary Albumod™ platform which is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life.

“The collaboration with Daiichi Sankyo further establishes our AlbumodTM platform as a leading half-life extension technology”, commented David Bejker, CEO of Affibody. “It is very rewarding to work with Daiichi Sankyo on a unique project targeting unmet medical needs.”

The technology will be applied on one undisclosed molecule from Daiichi Sankyo’s pipeline of proprietary protein therapeutics. Affibody will receive up-front and milestone payments as well as royalties on sales for licensing of the Albumod™ platform.

Further details of the agreement have not been disclosed.

About the Albumod™ platform
Affibody’s Albumod™ technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, potentially allowing for less frequent dosing and lower peak concentrations in blood with a decreased risk for adverse events. Furthermore, the Albumod™ technology may potentially be used to evade an immune response. In addition to these possible patient safety benefits, the overall treatment costs may be reduced.